Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
for Intermediate Risk Non-Muscle Invasive Bladder Cancer
49 locations incl. Mobile
Sponsor: Ferring Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06510374·Phase 3·Recruiting·Listed Jul 2024